Kallyope advances elismetrep after mid-stage migraine win

Kallyope is preparing to move its oral migraine candidate elismetrep toward registrational development after the TRPM8 antagonist posted positive results in a Phase IIb study. The US biotech said the drug delivered a favorable clinical profile, setting up plans to begin pivotal studies in mid-2026.

The update follows a stretch of mixed clinical readouts for Kallyope, which recently halted a separate mid-stage trial of migraine prospect K-645 for lack of efficacy. Its pivot to neurology came after two weight-loss programs disappointed in earlier testing, sharpening the company’s focus on alternative mechanisms in pain pathways.

In the Phase IIb trial, 431 US patients were randomized to elismetrep or placebo across four dose levels. The primary endpoint was pain freedom, with secondary measures including pain relief and freedom from symptoms such as photophobia, phonophobia, and nausea. Kallyope said the drug was well tolerated and that its performance was competitive with marketed therapies.